<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013804</url>
  </required_header>
  <id_info>
    <org_study_id>AMP-514-01</org_study_id>
    <secondary_id>D6020C00002 (AMP-514-01)</secondary_id>
    <nct_id>NCT02013804</nct_id>
  </id_info>
  <brief_title>A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, first-in-human dose-escalation study of MEDI0680 (AMP-514)&#xD;
      to evaluate the safety, tolerability, PK, immunogenicity (IM), and antitumor activity in&#xD;
      adult subjects with solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2013</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">May 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability; define Maximum Tolerated dose</measure>
    <time_frame>1 year</time_frame>
    <description>The primary objectives are to assess the safety and tolerability of multiple doses of MEDI0680 (AMP-514) and define the maximum tolerated dose (MTD) or highest protocol-defined dose of MEDI0680 (AMP-514) in the absence of exceeding the MTD.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Dose arms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI0680 (AMP-514)</intervention_name>
    <description>Study has planned dose escalation cohorts</description>
    <arm_group_label>Dose arms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age at time of study entry&#xD;
&#xD;
          2. Written informed consent and any locally required authorization (eg, Health Insurance&#xD;
             Portability and Accountability Act [HIPAA] in the USA) obtained from the subject/legal&#xD;
             representative prior to performing any protocol-related procedures, including&#xD;
             screening evaluations&#xD;
&#xD;
          3. Histologically- or cytologically-confirmed melanoma or clear-cell RCC that are&#xD;
             refractory to standard therapy or for which no standard therapy exists&#xD;
&#xD;
               1. Subjects must have failed, be intolerant to, or be ineligible for any potentially&#xD;
                  curative approved treatment, irrespective of line of therapy&#xD;
&#xD;
               2. No more than 3 prior lines of therapy&#xD;
&#xD;
          4. At least 1 measurable lesion per RECIST v1.1; subjects whose only measurable lesion is&#xD;
             a lymph node will be excluded&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance score of 0 or 1&#xD;
&#xD;
          6. For all tumor types, adequate organ and marrow function, as defined below:&#xD;
&#xD;
               1. Hemoglobin ³ 9.0 g/dL within first 2 weeks prior to first dose of MEDI0680&#xD;
                  (AMP-514)&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ³ 1.5 × 109/L (1,500/mm3)&#xD;
&#xD;
               3. Platelet count ³ 100 × 109/L (100,000/mm3)&#xD;
&#xD;
               4. Total bilirubin ≤ 1.5 × ULN except subjects with documented Gilbert's syndrome (&gt;&#xD;
                  3 × ULN) or liver metastasis, who must have a baseline total bilirubin ≤ 3.0 mg/&#xD;
&#xD;
               5. Alanine aminotransferase and AST ≤ 2.5 × ULN; for subjects with hepatic&#xD;
                  metastases, ALT and AST ≤ 5 × ULN&#xD;
&#xD;
               6. Serum creatinine ≤ 1.5 × ULN OR calculated creatinine clearance (CrCl) or 24-hour&#xD;
                  urine CrCl ≥ 50 mL/minute ▪ Cockcroft-Gault formula will be used to calculate&#xD;
                  CrCl; 24-hour urine CrCl will be derived using the measured creatinine clearance&#xD;
                  formula&#xD;
&#xD;
          7. Prior treatment toxicities must be ≤ Grade 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent enrollment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or the follow-up period of an interventional study&#xD;
&#xD;
          2. Receipt of any BRAF inhibitor (in metastatic melanoma), or investigational anticancer&#xD;
             therapy within 4 weeks prior to the first dose of MEDI0680 (AMP-514)&#xD;
&#xD;
          3. Prior exposure to immunotherapy, such as, but not limited to, other anti-CTLA-4,&#xD;
             anti-PD-1, or anti-PD-L1 antibodies, excluding therapeutic cancer vaccines&#xD;
&#xD;
          4. Major surgery (as defined by the investigator) within 4 weeks prior to first dose of&#xD;
             MEDI0680 (AMP-514) or still recovering from prior surgery&#xD;
&#xD;
          5. Other invasive malignancy within 2 years except for noninvasive malignancies such as&#xD;
             cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma&#xD;
             in situ of the breast that has/have been surgically cured&#xD;
&#xD;
          6. Prior allogeneic or autologous bone marrow or organ transplantation that requires use&#xD;
             of immunosuppressives&#xD;
&#xD;
          7. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to&#xD;
             NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion&#xD;
             criteria with the exception of alopecia. Subjects with irreversible toxicity that is&#xD;
             not reasonably expected to be exacerbated by MEDI0680 (AMP-514) may be included (eg,&#xD;
             hearing loss) after consultation with the MedImmune medical monitor&#xD;
&#xD;
          8. Active or prior documented autoimmune disease within the past 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>December 12, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

